18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy

18^th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
September 15-18, 2016 – Houston, TX, USA

Chairs: J Cortes, T Holyoake, TP Hughes
Co-Organizers: R Bhatia, M Copland, M Deininger, P Hari, D Perrotti, J Radich, D. Réa
Advisory Committee: J Apperley, S Branford, C Gambacorti-Passerini, F Guilhot, F-X Mahon, R Hehlmann, P Laneuville, G Saglio, C Schiffer, S Soverini, P Valent, R Van Etten

Speakers at this meeting will present the newest and often unpublished data that relate to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) Aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells and approaches to cure.

 
Upon completion of this CME activity, participants should be able to:
 

• Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.

• Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.

• Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.

• Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.

• Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.

• Assess the role of allogeneic stem cell transplantation in the management of CML.

• Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.

• Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.

• Discuss patient reported outcomes and their role in the management of patients with CML.

 THE PROGRAM WILL INCLUDE:

• John Goldman Prize
• Janet Rowley Prize
• ERSAP Prize
• Keynote lectures
• Special lectures
• Oral communications selected from submitted abstracts
• Brief oral communications selected from submitted abstracts
• Workshops for non-clinical scientists
• Clinical and biology manned poster walks
• Clinical symposium on Modern Diagnostics and
• Satellite symposia

DEADLINE TO SUBMIT ABSTRACTS IS PASSED.

https://esh.confex.com/esh/2016cml/gs/papers/index.cgi

Please find below the abstract guidelines: 

• Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured.
• Maximum number of words: 400
• You abstract will be submitted to the peer review procedure.

The following file types may be uploaded: HTML document (*.htm), HTML document (*.html), JPEG image (*.jpg), GIF image (*.gif), or PNG image (*.png).

Please check that you do receive an acknowledgement of your submitted abstract. If not, contact Pauline Jaillard
pauline.jaillard@univ-paris-diderot.fr

Your abstract can be selected for an oral presentation or a poster presentation. 

Poster board are 8 feet long (2,4 m long) and 4 feet high (1,2 m high) 

Please see below the poster board: 

Please register first to the conference. You will receive then a link for the accommodation. 

Royal Sonesta Houston
2222 West Loop S, Houston, TX 77027, USA

This full fee includes:

Your place in the conference room, conference materials, the teaching material, luncheons, welcome reception, refreshments throughout the conference. The full fee includes as well the Clinical Symposium on Modern Diagnostics.

CANCELLATION POLICY OF REGISTRATION FEE: In case of cancellation, up until one month prior to the beginning of the meeting, your registration fee will be reimbursed in full (less bank charges). If the cancellation is notified between 1 and 30 days prior to the beginning of the meeting, 50% of the registration fee will be reimbursed (less bank charges). Cancellations notified during the meeting will not be reimbursed. For credit card payments please register on-line first. Please note that ESH can accept VISA, MASTERCARD/EUROCARD, AMEX and CB.

Register Here